Two adolescent patients with coexistent Graves' disease and Moyamoya disease in Korea

Chong Kun Cheon, MD¹, Su Yung Kim, MD¹, Jae-Ho Yoo, MD²
¹Department of Pediatrics, Pusan National University School of Medicine, Yangsan, ²Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea

Moyamoya disease is a cerebrovascular condition that results in the narrowing of the vessels of the circle of Willis and collateral vessel formation at the base of the brain. Although relationships between Graves’ disease and cerebrovascular accidents in Moyamoya disease are obscure, the coexistence of the two diseases is noteworthy. Moyamoya disease has been rarely reported in adolescent patients with thyrotoxicosis. Recently, we encountered two adolescent Korean patients with Moyamoya disease associated with Graves’ disease who presented with episodic right-sided hemiparesis and syncope. These two girls who had Graves’ disease had no history of other diseases or head trauma. A thyroid function test revealed a euthyroid state and a high thyroid-stimulating hormone (TSH) receptor antibody titer at that time. The patients were diagnosed with Moyamoya disease based on brain magnetic resonance angiography and cerebral four-vessel angiography. The patients underwent cranial revascularization by encephalo-duroarterio-synangiosis as soon as a diagnosis was made, which resulted in successful symptom resolution. They fared well and had no additional neurological symptoms as of their last follow-up visits. Here, we report these two cases of confirmed Moyamoya disease complicated by Graves’ disease with a review of the literature, and discuss the possible association between the two diseases. To our knowledge, this is the first report in South Korea on Moyamoya disease associated with Graves’ disease in adolescents with a euthyroid.

Key words: Moyamoya disease, Graves’ disease, Hyperthyroidism

Introduction

Moyamoya disease is a disorder characterized by bilateral stenosis or occlusion of the terminal internal carotid artery and proximal portion of the anterior and middle cerebral arteries³. The pathogenesis of Moyamoya disease is unknown, but hyperactivity of cervical sympathetic nerves may contribute to stenosis of the cerebral arteries⁴. This disease has been reported in association with various disease entities, including hypothalamic-pituitary dysfunction, systemic lupus erythematosus, and Down syndrome⁴,⁵. Graves’ disease is an autoimmune antibody-mediated disease of the thyroid gland that can lead to the development of Moyamoya disease⁶. Many symptoms of thyrotoxicosis are similar to those of hyperactivity of the sympathetic nervous system, and thyroid hormones are thought to enhance the effects of sympathetic nervous activity⁷. However, coexistence of thyrotoxicosis and Moyamoya disease is extremely rare⁸. Until now, Moyamoya disease has been rarely reported in adolescent patients with thyrotoxicosis in Korea⁹. We report two girls with concurrent Moyamoya disease and Graves’ disease who presented episodes of syncope and right-sided hemiparesis.
Case reports

Case 1
A 12-year-old girl experienced a one minute episode of syncope with hyperventilation. She was diagnosed with Graves’ disease 10 months ago, taking high dose of maintenance methimazole 20 mg daily and followed up regularly at the pediatric outpatient clinic of Dong-A University Hospital. She had no past history of other disease or head trauma. She showed no specific neurologic sign on physical examination at that time, either.

On admission, laboratory investigations, including routine complete blood count (CBC), erythrocyte sedimentation rate (ESR), biochemistry, C3, C4, fibrinogen, antithrombin III, protein C and S, homocysteine, cryoglobulin, antinuclear antibody (ANA), antineutrophil cytoplasmic antibody (ANCA), anti-DNA, antiphospholipid antibodies, and antithrombin III, were all within normal ranges. Her serum level of triiodothyronine (T3), free thyroxine (FT4), thyroid stimulating hormone (TSH), and TSH receptor antibody was 213.36 ng/dL (reference range, 87–185 ng/dL), 1.64 ng/dL (reference range, 0.8–2.2 ng/dL), 0.24 uIU/mL (reference range, 0.3–4 uIU/mL), 112.66 U/L (reference range, <14.0 U/L), respectively. The patient was diagnosed with Moyamoya disease with typical stenosis of the right middle cerebral artery (MCA) based on brain magnetic resonance (MR) angiography (Fig. 1) and cerebral 4-vessel angiography (Fig. 2). Single-photon emission computed tomographic (SPECT) scans revealed cerebral hypoperfusion of the right parietal lobe and decreased vascular reserves of both occipital lobes (Fig. 3). The patient underwent cranial revascularization by encephalo-duroarterio-synangiosis (EDAS). To date, she has not presented a syncope attack since the surgery.

Case 2
A 15-year-old girl who had suffered from Graves’ disease for seven years visited the Pediatric Endocrinology Clinic at Pusan National University Children’s Hospital with episodic transient right-sided hemiparesis, along with the headache of 3 days’ duration. She was being treated with 10 mg of methimazole daily. On physical examination, she had goiter and central type sided facial palsy.

On admission, laboratory investigations, including routine CBC, ESR, biochemistry, C3, C4, fibrinogen, antithrombin III, factor VIII, factor V, protein C and S, homocysteine, cryoglobulin, ANA, ANCA, anti-DNA, antiphospholipid antibodies, and antithrombin III, were all within normal ranges. Her serum level of T3, FT4, TSH, and TSH receptor antibody was 1.07 ng/mL (reference range, 0.58–1.59 ng/mL), 0.99 ng/dL (reference range, 0.7–1.48 ng/dL), 0.01 uIU/mL (reference range, 0.27–4.20 uIU/mL), and 34.1 U/mL (reference range, <9.0 U/mL), respectively.

Brain MR imaging scans showed focal hemorrhage at the left insula, basal ganglia, and focal enhancing nodule, with small collateral vessels in basal ganglia and obliteration of both internal carotid artery (ICA) (Fig. 4). The patient was diagnosed with Moyamoya disease with typical stenosis of the ICA and MCA, based on cerebral angiography (Fig. 5). SPECT scans revealed cerebral hypoperfusion of the left parietal lobe, left thalamus, left basal ganglia, and medial temporal lobe without vascular reserve (Fig. 6).
The patient underwent cranial revascularization by EDAS. After surgery, the patient’s symptoms improved and she recovered power to her right upper and lower extremities. She fared well and had no additional neurological symptoms as of her last follow-up visit.

Discussion

Moyamoya disease is a cerebrovascular condition that results in the narrowing of the vessels of the circle of Willis and collateral vessel formation at the base of the brain. It becomes symptomatic whenever the collateral vessels fail to compensate for the cerebral blood flow deficit produced by the progressive stenotic lesion in the major cerebral arteries. Although relationships between Graves’ disease and cerebrovascular accidents in Moyamoya disease are obscure, the coexistence of both diseases is rare and noteworthy. To our knowledge, only 33 cases, including our case, of concurrent Moyamoya disease or intracranial arterial stenosis/occlusion and Graves’ disease have been described in the English literature. The interrelationship of these disorders is significant because the common pathogenesis to the two diseases may finally help us to elucidate the etiology of Moyamoya disease.

Cerebrovascular ischemic symptoms in Moyamoya disease are usually precipitated by activities associated with hyperventilation or thyrotoxicosis. In our case 1, the cerebrovascular ischemic symptom, syncope was aggravated by hyperventilation regardless of a state of euthyroid. Hyperventilation itself might cause cerebral vasoconstriction resulted in the decrement of cerebral blood flow to ischemic levels. Whereas it is believed that excess thyroid hormone in patients with Graves’ disease is harmful to arterial walls because it may alter vascular reactivity and
accelerate the formation of abnormal cerebral vessels\(^7\). In the majority of cases, cerebrovascular accidents occurred when patients were thyrotoxic, suggesting that thyroid hormones could have facilitated these accidents, possibly through hemodynamic changes and (or) sympathetic nervous system-mediated vasculopathy\(^7,\)\(^8\). Sympathetic nervous tone itself is not accentuated by thyrotoxicosis, but thyroid hormones are thought to increase sensitivity to the sympathetic nervous system\(^4\). Other disorders associated with Moyamoya disease have well-established autoimmune mechanisms of pathogenesis or are associated with arteritis that affects the cerebral arteries\(^7\). Such diseases include systemic lupus erythematosus, antiphospholipid syndrome, ulcerative colitis, tuberculosis, leptospirosis and post-radiation arteritis\(^7\). In clinical practice, the value of measuring sedimentation rate, protein S and C, antithrombin III, anticardiolipin antibodies, antinuclear factor, anti-Ro/SS-A, and anti-La/SS-B antibodies remains to be determined\(^11\). Another possible link between these disorders is atherosclerosis. Colleran et al.\(^12\) demonstrated the positive correlation between free thyroxine levels and both homocysteine and methylmalonic acid, suggesting the possibility of thyrotoxicosis inducing hyperhomocysteinemia. As homocysteinemia has been implicated in atherosclerotic and embolic disorders, it would be another key to the pathophysiology of Moyamoya disease\(^11\). It is practical to consider patients with both multiple arterial stenosis and Graves’ disease as being at risk for ischemic cerebrovascular events. Therefore, careful control of thyroid function is essential.

A recently published study observed that patients with Moyamoya disease were more likely to have elevated thyroid auto-antibodies than those with non-Moyamoya disease strokes, despite being in a euthyroid state\(^13\). Two patients in this study also had high levels TSH receptor antibody when syncope and right-side hemiparesis developed, even in a euthyroid state. This suggests a possible underlying immune process contributing to the development of Moyamoya disease\(^8\). In addition, there are familial cases of Moyamoya disease and Graves’ disease, indicating hereditary involvement in both diseases\(^14\). Taken together, genetic factors and autoimmunity may play important roles in the pathogenesis of the coexistence of Moyamoya disease and Graves’ disease\(^8\).

On the other hand, therapy with steroids, vasodilators, antibiotics, and nerve blocks appear to be of questionable benefit. Miyamoto et al.\(^15\) observed that superficial temporal artery-middle cerebral artery anastomosis with encephalomyosynangiosis was an appropriate surgical treatment for refractory cases of Moyamoya disease, and surgical revascularization may be considered for select patients. Adequate revascularization was confirmed on both cerebral angiography and SPECT studies, which were performed 3 to 6 months after surgery\(^15\). Our patients underwent surgery as
soon as a diagnosis was made, which resulted in successful resolutions of symptoms.

In conclusion, this is the first report of Moyamoya disease associated with Graves’ disease in two adolescent patients with euthyroid in Korea. We suggest that Moyamoya disease should be considered when patients with Graves’ disease, present with central nervous system symptoms, including headache, hemiparesis, and syncope. Further studies for large-scale national and multi-institutional patients are warranted to better understand the probable common underlying mechanisms of Moyamoya disease and Graves’ disease.

Conflict of interest

No potential conflict of interest relevant to this article was reported

Acknowledgments

We thank the patients and their families for participating in this study, which was supported by a 2-Year Research Grant of Pusan National University.

References

1. Ohba S, Nakagawa T, Murakami H. Concurrent Graves’ disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment. Neursurg Rev 2011;34:297-304.
2. Sasaki T, Nogawa S, Amano T. Co-morbidity of moyamoya disease with Graves’ disease. report of three cases and a review of the literature. Intern Med 2006;45:649-53.
3. Mootha SL, Riley WJ, Brosnan PG. Hypothalamic-pituitary dysfunction associated with Moyamoya disease in children. J Pediatr Endocrinol Metab 1999;12:449-53.
4. Malik S, Russman AN, Katramados AM, Silver B, Mitsias PD. Moyamoya syndrome associated with Graves’ disease: a case report and review of the literature. J Stroke Cerebrovasc Dis 2011;20:528-36.
5. Shen AL, Ryu SJ, Lin SK. Concurrent moyamoya disease and Graves’ thyrotoxicosis: case report and literature review. Acta Neurol Taiwan 2006;15:114-9.
6. Suzuki S, Mitsuyama T, Horiba A, Fukushima S, Hashimoto N, Kawamata T. Moyamoya disease complicated by Graves’ disease and type 2 diabetes mellitus: report of two cases. Clin Neurol Neurosurg 2011;113:325-9.
7. Lee R, Sung K, Park YM, Yu JJ, Koh YC, Chung S. A case of Moyamoya disease in a girl with thyrotoxicosis. Yonsei Med J 2009;50: 594-8.
8. Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg 2005;102: 1013-7.
9. Liu JS, Joo SH, Chen WH, Chang YY, Chen SS. A case of Graves’ diseases associated with intracranial moyamoya vessels and tubular stenosis of extracranial internal carotid arteries. J Formos Med Assoc 1994;93:806-9.
10. Garcin B, Louissaint T, Hosseini H, Blanc R, Fenelon G. Reversible chorea in association with Graves’ disease and moyamoya syndrome. Mov Disord 2008;23:620-2.
11. Booth F, Yanofsky R, Ross IB, Lawrence P, Oen K. Primary antiphospholipid syndrome with moyamoya-like vascular changes. Pediatr Neurosurg 1999;31:45-8.
12. Colleran KM, Ratliff DM, Burge MR. Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events. Endocr Pract 2003;9:290-5.
13. Kim SJ, Heo KG, Shin HY, Bang OY, Kim GM, Chung CS, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke 2010;41:173-6.
14. Tokimura H, Tajitsu K, Takashima H, Hirayama T, Tsuchiya M, Takayama K, et al. Familial moyamoya disease associated with Graves’ disease in a mother and daughter. Two case reports. Neurol Med Chir (Tokyo) 2010;50:668-74.
15. Miyamoto S, Kikuchi H, Karasawa J, Nagata I, Yamazoe N, Akiyama Y. Pitfalls in the surgical treatment of moyamoya disease. Operative techniques for refractory cases. J Neurosurg 1988;68:537-43.